GANTANOL
LOE ApproachingNDAORALTABLET
Approved
Aug 1965
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 2d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
GANTANOL is an oral tablet small-molecule NDA approved by Roche in 1965. The drug's mechanism of action, pharmacologic class, and specific indications are not currently documented in available data. It is administered orally as a tablet formulation.
LOE Approaching
Product is in advanced lifecycle stage with minimal current commercial activity; team restructuring or transition planning likely underway.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
GANTANOL currently has zero linked job openings, reflecting its mature and declining lifecycle stage. Career mobility and growth prospects on this product are severely limited.
Brand ManagerField Sales Representative
Worked on GANTANOL at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.